The anti-Pneumocystis carinii activity of atovaquone, dapsone and sulphamethoxazole alone and combined with dihydrofolate reductase (DHFR) inhibitors and macrolides was investigated against five clinical isolates of P. carinii. The susceptibility tests were performed by inoculation of the organisms on to cell monolayer and parasite count after 72 h incubation at 37°C. Culture plates were added to Dulbecco's modified Eagle's medium containing serial dilutions of atovaquone, dapsone and sulphamethoxazole alone or in combination with diaveridine, pyrimethamine, trimethoprim, azithromycin, clarithromycin and roxithromycin. Atovaquone, dapsone and sulphamethoxazole were found to be effective at levels well below the concentrations that could be achieved clinically, while DHFR inhibitors were shown to combine effectively with dapsone and sulphamethoxazole. No synergy could be demonstrated between atovaquone and DHFR inhibitors or macrolides. A mild synergic effect was noted when macrolides were combined with dapsone and sulphamethoxazole. Pyrimethamine (0.5 mg/L) combined with dapsone and trimethoprim (0.5 mg/L) combined with sulphamethoxazole exerted the strongest inhibitory effect.
Introduction
Pneumocystis carinii is one of the most common opportunistic pathogens of immunocompromised patients, especially those with HIV infection. Pneumocystosis is usually manifested as a diffuse infection of both lungs, but there may be systemic involvement of lymph nodes, kidney, liver and spleen. 1 Co-trimoxazole and pentamidine isethionate have been the principal drugs used in the therapy or prophylaxis of pneumocystis infection. Nevertheless, the high recurrence rate of pneumocystosis, the high frequency of adverse reaction to co-trimoxazole in patients with AIDS and the limitation of currently available anti-pneumocystis drugs has emphasized the need for new therapeutic and prophylactic approaches. 2, 3 In recent years, several in-vitro and in-vivo investigations using cell cultures, animal models, healthy volunteers and immunocompromised patients with P. carinii infection have been performed. These efforts have focused on screening several classes of compounds, which have exhibited activity against P. carinii and are non-toxic to animal and human cell cultures.
The dihydrofolate reductase (DHFR) inhibitors such as pyrimethamine, trimethoprim and epiroprim, have only a static effect on parasite growth and frequently cause adverse effect in AIDS patients. Nevertheless, trimethoprim in combination with sulphamethoxazole remains the mainstay in the treatment of P. carinii pneumonia. 4, 5 Other combinations, such as trimethoprim and dapsone, pyrimethamine and sulphadizine, and trimetrexate and sulphadiazine, also show activity against P. carinii, although the toxicity of these combinations varies among the individual agents. Trimethoprim, dapsone and sulphadiazine were well tolerated, whereas pyrimethamine and trimetrexate caused adverse reactions.
Several studies have been performed to investigate new drug synergy. For example, recent reports provide evidence that the combinations of clindamycin and primaquine or macrolides and sulphonamides exhibited high in-vitro and in-vivo activity against P. carinii. 1, [9] [10] [11] Similarly, 1,3--glucan inhibitors, terbinafine or some plant-derived terpenes such as the sesquiterpene bilobalide were also effective in P. carinii infections. [12] [13] [14] [15] However, although these agents may be useful for the treatment and prevention of pneumocystosis, their clinical use may be restricted by the unusually high incidence of adverse reactions in AIDS patients. Consequently, new drug combinations which are more effective and less toxic are needed to control this disease.
We investigated the in-vitro anti-P. carinii activity of various combinations among well known drugs such as sulphamethoxazole, dapsone, atovaquone, and DHFR inhibitors or macrolides.
Materials and methods

Organisms
Five clinical isolates of P. carinii were derived from bronchoalveolar lavages of five distinct AIDS patients who had not received prior anti-P. carinii therapy.
Drugs
Atovaquone (Wellcome Italia, Rome, Italy), sulphamethoxazole (Sigma-Aldrich, Milan, Italy), azithromycin (Pfizer/Roerig, Rome, Italy), clarithromycin (Abbott, Rome, Italy), roxithromycin (Roussel Pharma, Milan, Italy), trimethoprim (Sigma-Aldrich), diaveridine (SigmaAldrich) and pyrimethamine (Sigma-Aldrich) were dissolved in 50% methanol/50% acetone at a concentration of 1 mg/mL. Dapsone (Sigma-Aldrich) was initially dissolved in dimethylsulphoxide (Sigma-Aldrich) at a concentration of 5 mg/mL and then diluted to a concentration of 1 mg/mL in ethanol. Solutions of drugs were made fresh on the day of assay or stored at 70°C in the dark for short periods.
Parasite preparation
Specimens were homogenized in an equal volume of phosphate-buffered saline by forced passage through a thin needle in order to disaggregate the clumps and then filtered through sterile gauze. The homogenate was centrifuged (1800g for 15 min) and the pellet was resuspended in physiological saline. Contaminating bacteria were partially eliminated by four washes in 10 mL of physiological saline followed by incubation in phosphatebuffered saline containing ampicillin (2000 mg/L) and streptomycin (2000 mg/L), for 4 h at 37°C. Organisms were pelleted by centrifugation (1800g for 20 min), resuspended in Dulbecco's modified Eagle's medium (DMEM) (Bio-Whittaker, Walkersville, USA), counted by methenamine silver stain to detect cysts and with Giemsa stain for counting of P. carinii nuclei and finally aliquoted for culture. In addition, unstained smears were examined by phase-contrast microscopy for the presence of cysts. The final inoculum was 10 3 -10 4 P. carinii organisms/mL.
Cell cultures
The human lung epithelial cell line A549 was used. The cells were maintained at 37°C in 24-well plates in medium containing DMEM, 10% fetal calf serum, 1% L-glutamine, penicillin (200,000 U/L), streptomycin (200 mg/L) and amphotericin B (0.5 mg/L). These drugs, which are routinely used in the tissue culture system, do not inhibit P. carinii growth. 2 Cultures were initiated by adding 1 mL of inoculum to an adherent layer of 50-70% confluent A549 cells. After incubation for 4 h at 37°C in 5% CO 2 to allow attachment and penetration of sporozoites, the monolayers were washed with DMEM to remove noninvasive sporozoites, residual cysts and nonadherent epithelial cells, and 2 mL of new growth medium with or without antimicrobial agents was added. Infected cell cultures were kept at 37°C with 5% CO 2 atmosphere throughout the study. Pneumocystis carinii sporozoites were added at a concentration of 10 3 -1 0 4 sporozoites per plate. The monolayers were incubated at 37°C in 5% CO 2 atmosphere for 2 weeks. Samples of supernatant (0.05 mL) were withdrawn daily from each triplicate flask and evaluated for P. carinii trophozoite and cyst counts by Giemsa and methenamine silver staining.
In-vitro studies
Analysis of results
The activity of each agent and combination was evaluated by parasite count from plates with antimicrobial-supple-mented medium compared with control plates without drugs.
The average number of P. carinii parasites/mL standard deviation was calculated by counting 50 oil immersion fields ( 1000 magnification) of each of three slides.
The 50 and 90% inhibitory concentrations (IC 50 and IC 90 , respectively) of the drug were defined as the concentrations required to produce 50 and 90% reduction, respectively, in the mean cyst or nucleus counts compared with controls without drug, after 72 h incubation in the presence of drugs.
Each drug concentration was defined as inhibitory if it caused a significant decrease in parasite count when compared with control plates. The significance of differences was evaluated by Student's t-test. In addition, to assess the efficacy of drug combinations, the significance of differences between results obtained by testing atovaquone, dapsone and sulphamethoxazole in combination were compared by Student's t-test with those from control plates.
A P-value of 0.05 was considered significant.
Results
In control plates, with an inoculum of 10 3 -10 4 organisms/mL, the numbers of P. carinii increased four-to fivefold, with peak numbers reached on day 3. For this reason, the drug activities in plates with antibioticsupplemented medium were evaluated on the basis of the parasite counts performed after 72 h incubation. Our data showed slight reduction in the number of trophozoites and cysts after day 5 and a rapid decrease after day 10.
The activities of the studied drugs against P. carinii are summarized in Table I . Atovaquone and sulphamethoxazole tested alone were able to inhibit the development of trophozoites completely at a concentration of 64 mg/L. However, only atovaquone 64 mg/L showed the same effectiveness against cysts. When the activities of single agents were compared by IC 90 , dapsone exhibited activity superior to other agents.
The results of combination studies are shown in Tables  II-IV. It is important to note that the activity of atovaquone, as shown by the IC 50 , remained virtually unchanged whether it was alone or combined with macrolides or DHFR inhibitors, while the IC 90 based on the mean cysts count showed a two-fold decrease when it was combined with pyrimethamine, trimethoprim and clarithromycin.
A four-fold increase in the activity of dapsone was observed when the drug was combined with DHFR inhibitors. However, synergy with dapsone-DHFR inhibitor combinations was significantly more evident w i t h pyrimethamine (Table III) . The anti-trophozoite activity of dapsone combined with DHFR inhibitors and macrolides did not differ significantly from that exhibited against cysts.
The activity of sulphamethoxazole was improved when this drug was combined with trimethoprim at concentrations of 0.5 mg/L: the IC 50 and IC 90 values of the combination were four-fold lower than that of sulphamethoxazole alone. The IC 50 and IC 90 values of sulphamethoxazole were slightly decreased by addition of macrolides. However, the activity of sulphamethoxole was better when it was combined with clarithromycin.
In addition, the results given in Tables I-IV indicate that the activities of the drugs showed some differences on the basis of the development stage detected. For example, comparing P. carinii cyst or trophozoite counts, atovaquone showed the highest activity against cysts, while dapsone and sulphamethoxazole showed the highest activity against trophozoites. This phenomenon was particularly evident when IC 90 values were considered.
Atovaquone and dapsone were inhibitory at a concentration of 4 mg/L, while sulphamethoxazole was inhibitory at a concentration of 8 mg/L (P 0.05). Drug combinations were effective only when the highest concentrations of DHFR and macrolides were used.
Discussion
In this study we have developed a quantitative system to evaluate the in-vitro activity of several agents tested alone and in combination. The A549 line was used in our susceptibility studies because it can be grown in multi-well tissue culture plates which allow more agents to be evaluated with smaller amounts of drugs. In our study, evaluation of antimicrobial agents was based on a comparison of P. carinii growth in treated and control cultures over the 72 h culture period and the parasite growth was assessed by sampling the supernatant and quantifying cysts and nuclei. Preliminary experiments indicated that the organism grows in clusters which can be seen both in the supernatant and attached to the cell monolayer. Although our technique probably underestimates the extent of P. carinii replication, it has proven to be reliable and reproducible. Cyst counts seem easier to perform because in our culture system the cellular debris obscures the detection of [1] [2] [3] 8 the interaction among these drugs and other antimicrobial agents such as macrolides and DHFR inhibitors has not yet been extensively studied. In our study we have explored the feasibility of combining effective doses of these agents for controlling in-vitro replication of P. carinii.
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Our results confirm that atovaquone alone is rather effective against P. carinii in vitro as it could inhibit the growth of trophozoites and cysts (IC 90 ) at concentrations of 32 mg/L and 64 mg/L, respectively. Dapsone used alone had strong activity against trophozoites, producing a 90% reduction of their numbers at concentration of 16 mg/L. Although this concentration did not produce a 90% reduction in the number of cysts, its activity against cysts was higher than that seen for the other two agents. In fact, at a concentration of 16 mg/L, dapsone produced a 83.4% reduction in the number of cysts (data not shown). Furthermore, sulphamethoxazole is less effective in vitro against P. carinii than dapsone, when used as single agent, producing a 90% reduction of trophozoites and cysts at concentrations of 32 mg/L and 64 mg/L, respectively. Macrolides and DHFR inhibitors were not able to inhibit the growth of the organisms, even at drug concentrations that exceeded those that could be achieved clinically. Pyrimethamine (0.5 mg/L) combined with dapsone and trimethoprim (0.5 mg/L) combined with sulphamethoxazole exerted the strongest inhibitory effect.
In conclusion, this study has shown in-vitro anti-P . c a r i n i i activity of atovaquone, dapsone and sulpha-methoxazole at levels well below the concentrations that could be achieved clinically, while DHFR inhibitors were shown to combine effectively with sulphones and sulphonamides. On the other hand, while no synergy could be demonstrated between atovaquone and macrolides, a mild synergic effect was noted when clarithromycin was combined with dapsone and sulphamethoxazole.
Atovaquone acts by inhibiting the dihydroorotate dehydrogenase, a key enzyme in pyrimidine biosynthesis, linked to the mitochondrial respiratory chain and catalysing the conversion of dihydroorotate to orotate. 8 Sulphones and sulphonamides exert their effects by inhibiting the catalytic activity of the enzyme dihydropteroate synthetase (DHPS), a key enzyme in the incorporation of para-aminobenzoic acid (PABA), a precursor of de novo folate synthesis. 16 Our findings indicate the presence of synergic effects between dapsone and DHFR inhibitors, dapsone and macrolides, sulphamethoxazole and DHFR inhibitors, and sulphamethoxa- The reason why macrolides have a positive interaction with sulphones and sulphonamides is unclear. The antibacterial activity of the macrolides is known to result from their ability to inhibit protein synthesis by binding to the transpeptidation site of the larger ribosomal subunit. Thus, it is logical that these agents could also affect P. carinii by inhibiting protein synthesis. Macrolides have shown synergy with other drugs against fungi and protozoa. For example, erythromycin demonstrated synergy with sulphisoxazole for treatment of P. carinii infection in rats, 17 and inhibited protein synthesis of fungi such as Saccharomyces cerevisiae and Schizosaccharomyces pombe.
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1 Despite this the problem about the real nature of P. carinii and its taxonomic classification still remains unresolved. 18 Moreover, in our study synergy was not clearly demonstrated because we did not calculate a fractional inhibitory concentration index when atovaquone, dapsone and sulphamethoxazole were combined with other drugs and, therefore, these interactions could be characterized as additive.
Further investigations are needed to characterize the activity of antimicrobial agents against P. carinii so as to identify more active compounds and to clarify the molecular mechanisms of any possible synergy. Finally, the results obtained with these different combinations indicate that it may be beneficial to combine DHPS inhibitors with DHFR inhibitors and macrolides for efficient control of P. carinii infection. 
